The Future of Psychedelic Medicine

Our Story

Find out what inspires us to support mental health disorders.

Our Mission

Supporting innovative therapies to help humans thrive.

Our Team

Multi-Disciplinary Collaboration
creating positive experiences and outcomes.

Mission

Using a foundation of evidence-informed research, we want to empower people to achieve their potential and thrive.

CORE PILLARS

HAVN Labs

Psychedelic medicine is the frontier of mental health and wellness

Social attitudes and behaviours towards mental health are shifting away from pharmaceuticals in favour of sustainably resourced compounds derived from fungi and plant medicines.


350 Million

People globally are affected by a form of depression.

1 Trillion

Dollars lost annually in global workforce productivity due to depression and anxiety.

0

Formulas standardized across clinical studies of psychedelic compounds.

Havn Life is part of a global community taking an active role in formulations and research for microdosing therapies which have shown effectiveness in addressing mental health and performance.

Press Releases

Havn Life announces DTC Eligibility of Its Common Shares in the United States

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of …

Read More →
Press Releases

Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), announces the departure of Ms. Barinder Rasode …

Read More →
Press Releases

Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.

Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex Vancouver, BC – Havn Life Sciences Inc. (CSE: …

Read More →
Scroll to Top